Achiko AG Signs Major Marketing and Sales Agreement with World’s Largest Islamic Association for its AptameX Covid-19 Rapid Test
April 20, 2022 07:45 ET
|
Achiko AG
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the...
Achiko Secures up to USD$12.6 Million Equity and Debt Financing Lines with RiverFort Over Three Years
April 20, 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, April 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces the...
Achiko AG Production and Sales Update
March 03, 2022 07:30 ET
|
Achiko AG
Unique Chemistry with DNA Aptamers Completing Pre-Sales Validation TestingCompleting Pre-Sales Validation Testing in Indonesia ZURICH, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Ad...
Achiko AG Research Paper and Commercialization Update
February 14, 2022 07:30 ET
|
Achiko AG
Calibration study results now available in draft paper on medRxiv, a preprint platform for health sciences, as “DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for...
Achiko AG Strengthens Senior Team with Appointment of Head of Corporate Development
January 27, 2022 07:30 ET
|
Achiko AG
Achiko AG appoints David Hodge to the role of Head of Corporate Development in SwitzerlandDavid Hodge will oversee Corporate Affairs, and Strategic and Corporate DevelopmentBoard Director Christophe...
Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology
January 18, 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post:...
Achiko AG Reports Breakthrough Calibration Results for its AptameX™ Covid-19 Rapid Test Technology
January 14, 2022 07:30 ET
|
Achiko AG
AptameX™ Covid-19 rapid calibration successfully classified 100% of results indicatinga likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.Results were...
Achiko AG Completing CHF4.85m Financing and Changes to Senior Team
December 31, 2021 07:30 ET
|
Achiko AG
Completing CHF 4.85 Million Placement from August 2021Board Director Christophe Laurent to RetireAppoints Adam O’Keeffe as Ad Interim Chief Financial Officer ZURICH, Switzerland, Dec. 31, 2021 ...
Achiko AG Looks Back at Pivotal Year and Reaffirms Commitment to Provide Affordable and Accurate COVID-19 Testing Solution
December 23, 2021 07:30 ET
|
Achiko AG
2021 Was a Pivotal Year for Achiko, Marked by Seminal Developments and ApprovalsWith AptameX™, Achiko Launched an Innovative DNA Aptamer Saliva-Based Rapid Test for Covid-19 as an Affordable and...
Achiko AG’s Shares Begin Trading on the OTCQB Market
December 20, 2021 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468; www.achiko.com) (“Achiko”, the “Company”), a global healthtech company which has...